Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials).
- DOI
- 10.1007/s40744-026-00852-3
- Published
- 2026-05-16
- Container
- Rheumatol Ther
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s40744-026-00852-3,
title = {Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials).},
author = {Fleischmann RM and Strand V and Feist E and Lisitsyna T and Sparks JA and Nasonov E and Samsonov M and Grishin S and Egorova A and Kuzkina S and Smolen JS.},
year = {2026},
journal = {Rheumatol Ther},
doi = {10.1007/s40744-026-00852-3},
url = {https://doi.org/10.1007/s40744-026-00852-3}
}RIS
TY - JOUR TI - Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials). AU - Fleischmann RM AU - Strand V AU - Feist E AU - Lisitsyna T AU - Sparks JA AU - Nasonov E AU - Samsonov M AU - Grishin S AU - Egorova A AU - Kuzkina S AU - Smolen JS. PY - 2026 JO - Rheumatol Ther DO - 10.1007/s40744-026-00852-3 UR - https://doi.org/10.1007/s40744-026-00852-3 ER -
APA
RM, F., V, S., E, F., T, L., JA, S., E, N., M, S., S, G., A, E., S, K., & JS., S. (2026). Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials).. Rheumatol Ther. https://doi.org/10.1007/s40744-026-00852-3
Source records
- europe-pmc · retrieved 2026-09-25T04:56:40.721Z